SuperworthArmata Pharmaceuticals PE ratio ARMP
Share price divided by earnings per share over the last twelve months, since 2013.
- Today, Oct 23, 2026
- n/m
- losses over the last year
- Last meaningful
- 8.4×
- Nov 2015
- Earnings per share, 12 months
- −$7.59
- to Jun 30, 2026
- Share price
- $3.64
- Oct 23, 2026
- Peer median
- 14.9×
Armata Pharmaceuticals has no meaningful PE ratio today: it lost $7.59 a share over the last twelve months, and a PE needs earnings.
It was last meaningful in Nov 2015, at 8.4×.
It has had no meaningful PE for most of its history, so the chart below shows the earnings per share a PE divides the price by.
Earnings per share over time
A PE divides the share price by these earnings. While they were a loss or a sliver, the PE meant nothing, so this chart shows the earnings themselves.
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$4.81 | n/a |
| FY2024 | −$1.05 | n/a |
| FY2023 | −$1.98 | n/a |
| FY2022 | −$1.09 | n/a |
| FY2021 | −$0.97 | n/a |
| FY2020 | −$1.42 | n/a |
| FY2019 | −$2.70 | n/a |
| FY2018 | −$6.74 | n/a |
| FY2017 | −$52.36 | n/a |
| FY2016 | −$367.92 | n/a |
| FY2015 | −$652.40 | n/a |
| FY2014 | −$715.40 | n/a |
| FY2013 | −$4760.00 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$0.27 | n/a | −$7.59 | |
| Q1 FY26 | −$3.16 | n/a | −$7.77 | |
| Q4 FY25 | −$3.42 | −8650% | −$4.81 | |
| Q3 FY25 | −$0.74 | n/a | −$1.35 | |
| Q2 FY25 | −$0.45 | n/a | −$0.76 | |
| Q1 FY25 | −$0.20 | n/a | −$0.56 | |
| Q4 FY24 | $0.04 | n/a | −$1.05 | |
| Q3 FY24 | −$0.15 | n/a | −$1.64 | |
| Q2 FY24 | −$0.25 | n/a | −$2.35 | |
| Q1 FY24 | −$0.69 | n/a | −$2.27 | |
| Q4 FY23 | −$0.55 | n/a | −$1.98 | |
| Q3 FY23 | −$0.86 | n/a | −$1.72 |
Against its peers
Companies in Healthcare nearest Armata Pharmaceuticals' size, closest first, today.
| Company | PE ratio |
|---|---|
| ARMPArmata Pharmaceuticals | n/m |
| KEQUKewaunee Scientific | 11.9× |
| ICCCImmucell | 128× |
| PDEXPro DEX | 15.1× |
| PLXProtalix BioTherapeutics | 11.1× |
| NATRNatures Sunshine Products | 12.0× |
| ELMDElectromed | 20.1× |
| UTMDUtah Medical Products | 22.6× |
| LFVNLifevantage | 14.7× |
| INFUInfuSystem | 34.0× |
| SPROSpero Therapeutics | 10.1× |
| Peer median | 14.9× |
What the PE ratio tells you
Share price divided by earnings per share over the last twelve months. It is the price tag on a dollar of profit: 20× means you pay $20 for $1 of yearly earnings.
Blank while earnings are negative. A very low PE can mean the market expects profits to fall, so read it with growth and the company's own history.
More on Armata Pharmaceuticals
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.